Xiaoyu Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoyu Sun has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Bing Sun
Key Laboratory of Multi-Cell Systems, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China
5 shared publications Chunyan Yi
Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
3 shared publicationsJichao Yang
School of Life Science and Technology, ShanghaiTech University, Shanghai, China
3 shared publicationsJiefang Xu
Division of Life Sciences and Medicine, University of Science and Technology of China, hefei, China
3 shared publicationsLiyan Ma
Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
3 shared publicationsRan Wang
Division of Life Sciences and Medicine, University of Science and Technology of China, hefei, China
3 shared publications
Latest Publications
- Open Access
- 25 June 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (8) , 110420
An anti-CD47 antibody binds to a distinct epitope in a novel metal ion-dependent manner to minimize cross-linking of red blood cells
- 25 June 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (8) , 110420
Open AccessAn anti-CD47 antibody binds to a distinct epitope in a novel metal ion-dependent manner to minimize cross-linking of red blood cells
- Open Access
Bispecific targeting of 4-1BB and CCR8 boosts antitumor immunity via Ti-Treg depletion and CD8+ activation
- Open Access
- 28 April 2025
- Published by Taylor & Francis in OncoImmunology
- Vol. 14 (1) , 2497171
TNFR2/CCR8 bispecific antibody enhances antitumor activity through depleting Ti-Tregs and boosting effector CD8 + T cell function
Modulation or depletion of tumor-infiltrating Tregs (Ti-Tregs) is a promising strategy in the field of antitumor immunotherapy. However, this approach poses challenges due to the diversity within the Treg population and the lack of precision in targeting Ti-Tregs. To selectively and efficiently eliminate Ti-Tregs while sparing other immune cells, we developed a bispecific antibody, FT10-Fab, targeting TNFR2 and CCR8, which are highly expressed on Ti-Tregs. Our results showed that FT10-Fab outperformed the monotherapies in several tumor models by significantly reducing the proportion of Ti-Tregs while increasing the proportion of CD8+ T cells. FT10-Fab was able to target and eliminate Ti-Tregs expressing TNFR2 or CCR8 (TNFR2+or CCR8+ Tregs), particularly TNFR2+ CCR8+ Tregs, which are the most important proliferative and protumorigenic Tregs. In addition, FT10-Fab relies on CD8+ T cells for its antitumor function and induces robust immune memory. Furthermore, the combination of FT10-Fab with PD-1 blockade showed synergistic therapeutic efficacy against tumors by significantly suppressing Tregs and enhancing effector CD8+ T cell function. Taken together, our findings suggest that precision depletion of Ti-Tregs via the bispecific TNFR2/CCR8 antibody is a potential therapeutic for cancer immunotherapy, while combination with anti-PD1 amplifies the antitumor effect.
- 28 April 2025
- Published by Taylor & Francis in OncoImmunology
- Vol. 14 (1) , 2497171
Open AccessTNFR2/CCR8 bispecific antibody enhances antitumor activity through depleting Ti-Tregs and boosting effector CD8 + T cell function
Modulation or depletion of tumor-infiltrating Tregs (Ti-Tregs) is a promising strategy in the field of antitumor immunotherapy. However, this approach poses challenges due to the diversity within the Treg population and the lack of precision in targeting Ti-Tregs. To selectively and efficiently eliminate Ti-Tregs while sparing other immune cells, we developed a bispecific antibody, FT10-Fab, targeting TNFR2 and CCR8, which are highly expressed on Ti-Tregs. Our results showed that FT10-Fab outperformed the monotherapies in several tumor models by significantly reducing the proportion of Ti-Tregs while increasing the proportion of CD8+ T cells. FT10-Fab was able to target and eliminate Ti-Tregs expressing TNFR2 or CCR8 (TNFR2+or CCR8+ Tregs), particularly TNFR2+ CCR8+ Tregs, which are the most important proliferative and protumorigenic Tregs. In addition, FT10-Fab relies on CD8+ T cells for its antitumor function and induces robust immune memory. Furthermore, the combination of FT10-Fab with PD-1 blockade showed synergistic therapeutic efficacy against tumors by significantly suppressing Tregs and enhancing effector CD8+ T cell function. Taken together, our findings suggest that precision depletion of Ti-Tregs via the bispecific TNFR2/CCR8 antibody is a potential therapeutic for cancer immunotherapy, while combination with anti-PD1 amplifies the antitumor effect.
- 3 December 2024
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 22 (1) , 127-130
Children exhibit a robust B-cell response to Omicron BA.2 after breakthrough infection with limited influence from the original antigenic sin
- 3 December 2024
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 22 (1) , 127-130
Children exhibit a robust B-cell response to Omicron BA.2 after breakthrough infection with limited influence from the original antigenic sin
- 23 December 2023
- Published by Elsevier in Antiviral Research
- Vol. 221, 105785
Broadly neutralizing antibodies to combat influenza virus infection
- 23 December 2023
- Published by Elsevier in Antiviral Research
- Vol. 221, 105785
Broadly neutralizing antibodies to combat influenza virus infection